SEC Form 4 · accession 0000899243-17-000226
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian T Clark
Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 4, 2017 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $14.43 | Jan 3, 2017 | A | 30,000 | A | — | Jan 3, 2027 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from January 3, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.